Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
ALZAMEND NEURO, INC.
Alzamend NeuroAI Executive Summary
AI-powered analysis of 8-K filing content
Alzamend Neuro received a Nasdaq notification on March 20, 2026, that its stockholders' equity of $2.2 million fell below the required $2.5 million threshold for continued listing on the Nasdaq Capital Market, creating potential delisting risk and investor confidence concerns.
Key Takeaways
Company's stockholders' equity ($2.2M) is $300K below Nasdaq's minimum requirement ($2.5M) as of January 31, 2026
This is a notification letter, not an immediate delisting, but signals non-compliance with exchange listing standards
2 more takeaways